A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Biliary cancer; Biliary tract disorders
- Focus Therapeutic Use
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.
- 14 Jun 2017 Planned initiation date changed from 14 Jun 2017 to 15 Jun 2017.
- 08 Jun 2017 Planned initiation date changed from 13 Jun 2017 to 14 Jun 2017.